Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · IEX Real-Time Price · USD
0.750
-0.020 (-2.58%)
May 17, 2024, 4:00 PM EDT - Market closed
Spruce Biosciences Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Spruce Biosciences stock have an average target of 3.60, with a low estimate of 2.00 and a high estimate of 7.00. The average target predicts an increase of 380.00% from the current stock price of 0.75.
Analyst Consensus: Hold
* Price targets were last updated on Mar 14, 2024.
Analyst Ratings
The average analyst rating for SPRB stock from 8 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 0 | 0 | 0 |
| Buy | 5 | 5 | 5 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 14, 2024 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $9 → $2 | Buy → Hold | Downgrades | $9 → $2 | +166.67% | Mar 14, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $8 → $3 | Buy | Maintains | $8 → $3 | +300.00% | Mar 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Mar 14, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $9 → $2 | Buy → Hold | Downgrades | $9 → $2 | +166.67% | Mar 14, 2024 |
Financial Forecast
Revenue This Year
4.70M
from 10.09M
Decreased by -53.44%
Revenue Next Year
2.55M
from 4.70M
Decreased by -45.71%
EPS This Year
-1.14
from -1.24
EPS Next Year
-1.03
from -1.14
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 12.1M | 10.5M | 568.1M | 41.2M | 198.1M |
| Avg | 4.7M | 2.6M | 111.5M | 14.2M | 75.7M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 19.7% | 123.5% | 22,176.5% | -63.0% | 1,292.4% |
| Avg | -53.4% | -45.7% | 4,272.2% | -87.2% | 432.1% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.70 | -0.58 | -0.40 | -0.62 | 2.39 |
| Avg | -1.14 | -1.03 | -1.11 | -0.83 | 0.32 |
| Low | -1.56 | -1.83 | -2.97 | -1.34 | -0.81 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.